Northern Trust Corp Invests $1.09 Million in AC Immune SA (NASDAQ:ACIU)

Northern Trust Corp purchased a new stake in AC Immune SA (NASDAQ:ACIU - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 403,031 shares of the company's stock, valued at approximately $1,088,000. Northern Trust Corp owned about 0.41% of AC Immune at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ACIU. Quinn Opportunity Partners LLC acquired a new position in shares of AC Immune during the 4th quarter worth about $27,000. Boothbay Fund Management LLC acquired a new position in shares of AC Immune during the 4th quarter worth about $38,000. RPO LLC acquired a new position in shares of AC Immune during the 4th quarter worth about $51,000. Geode Capital Management LLC increased its stake in shares of AC Immune by 9.9% during the 4th quarter. Geode Capital Management LLC now owns 64,090 shares of the company's stock worth $173,000 after purchasing an additional 5,794 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of AC Immune by 130.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock worth $355,000 after purchasing an additional 74,358 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Trading Down 3.8%

NASDAQ ACIU traded down $0.07 during trading on Monday, reaching $1.65. The company's stock had a trading volume of 128,298 shares, compared to its average volume of 161,325. The firm has a market capitalization of $165.17 million, a price-to-earnings ratio of -3.58 and a beta of 1.62. AC Immune SA has a 12 month low of $1.43 and a 12 month high of $4.98. The firm has a 50 day moving average price of $1.65 and a 200 day moving average price of $2.35.

AC Immune (NASDAQ:ACIU - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. The business had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.99 million. On average, equities analysts forecast that AC Immune SA will post -0.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on ACIU shares. HC Wainwright reduced their target price on shares of AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Wall Street Zen upgraded shares of AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.